Aarti Drugs Q2 profit rises 83% on 26.6% revenue growth
In short
Aarti Drugs reported stronger Q2 results. Net profit rose 83.2% year on year to ₹82.9 crore. Revenue climbed 26.6% to ₹826.2 crore, and EBITDA increased 60.6% to ₹135.4 crore.
The company also said its EBITDA margin improved to 16.4%. This matters because it shows better earnings quality, but the reporting does not say what drove the gains.
What the reporting says
Aarti Drugs reported an 83.2% year-on-year rise in Q2 net profit to ₹82.9 crore, with revenue up 26.6% to ₹826.2 crore and EBITDA up 60.6% to ₹135.4 crore. The company also said EBITDA margin improved by 350 basis points to 16.4%, according to the publisher-supplied summary. The immediate market takeaway is stronger operating performance, but the underlying business drivers were not stated in the available reporting.
Why it matters
Aarti Drugs reported Q2 results showing higher profit, revenue, and EBITDA, with margin expansion to 16.4%. The publisher-supplied summary points to stronger operating performance, but it does not state which products, markets, or cost factors drove the improvement. The immediate implication is a positive read-through for the company’s quarterly earnings momentum, while the broader business cause remains unknown in the available reporting.